Coronado Biosciences Signs Research Collaboration and License Agreement With Freie Universitat Berlin for Secretory Products of Trichuris Suis

BURLINGTON, Mass., Feb. 22, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the signing of a sponsored research agreement and a joint ownership and exclusive license agreement with Freie Universität Berlin for the identification and evaluation of secretory proteins from Trichuris suis. The evaluation will be done in various pre-clinical in vitro and animal models which will further describe the mechanism of action for TSO (Trichuris suis ova or CNDO-201) and potentially lead to newly identified immune regulatory pharmaceutical agents.

Back to news